Erythropoietin (EPO) is used to treat anaemia associated with chronic kidney disease (CKD). Hypoxia is associated with anaemia and is known to cause a decrease in cytochrome P450 (P450) expression. As EPO production is regulated by hypoxia, we investigated the role of EPO on P450 expression and function.
Introduction
Chronic kidney disease (CKD) is a progressive, irreversible loss of renal function characterized by decreasing glomerular filtration rate. Rates of CKD in the population are increasing, largely because of increasing prevalence of associated comorbidities such as diabetes and hypertension. Patients with CKD are commonly prescribed more than seven drugs concurrently, with even higher prescription rates among dialysis patients, to manage their CKD and comorbidities (Talbert, 1994; Manley et al., 2004) . Drug dosing in CKD is complicated by altered pharmacokinetic profiles, involving reduced renal and non-renal clearance of drugs (Velenosi and Urquhart, 2014) . These pharmacokinetic alterations and the heavy medication burden result in high rates of adverse drug events in patients with CKD (Manley et al., 2004; Nolin et al., 2009) . Accordingly, the US Food and Drug Administration has published recommendations for evaluation of drug pharmacokinetics, dosing and labelling in patients with renal impairment (FDA, 2010) .
Non-renal clearance of most drugs largely involves drug metabolism. In fact, the majority of prescribed drugs require some degree of metabolism prior to elimination from the body. The primary site of drug metabolism is the liver, and these reactions are primarily mediated by cytochrome P450 (P450) enzymes (Wienkers and Heath, 2005) . CYP3A4/5 is responsible for the metabolism of 30-50% of all clinically used drugs with the CYP2C subfamily accounting for metabolism of approximately 24% of drugs. (Wrighton et al., 1996; Nolin et al., 2003; Zanger and Schwab, 2013) . Previous studies using animal models of moderate and severe CKD have shown decreased hepatic expression and function of CYP2C, the most abundant P450 in rat liver, and CYP3A (Leblond et al., 2000; Velenosi et al., 2012) .
Erythropoietin (EPO) is a glycoprotein hormone produced by the interstitial cells of the kidney (Lacombe et al., 1988) . Normally produced by the healthy kidney in response to hypoxia, the primary action of EPO is to control proliferation and differentiation of erythroid progenitor cells. Accordingly, EPO is commonly used to treat anaemia associated with CKD and is also used in the treatment of other anaemiarelated disorders such as those encountered during chemo-therapy, treatment of HIV and rheumatic disease. Specific to CKD, haemodialysis patients require doses of recombinant human EPO three times per week to maintain blood haematocrit required for sufficient tissue oxygenation (Eschbach, 2002) .
Although investigated for decades in the regulation of red blood cell production, other non-haematopoietic roles of EPO have been recently discovered. The non-haematopoietic effects of EPO signalling have been largely investigated in the protection of cells from ischemia and reperfusion injury in the CNS, heart, kidney and liver. The direct effects of EPO are mediated by interaction at the surface of cells, including hepatocytes, that express the EPO receptor (Pinto et al., 2008) . Further, recent evidence also suggests that EPOmediated signalling is able to activate hepatic transcription factors including the nuclear receptor liver X receptor (LXR; Pinto et al., 2008; Lu et al., 2010) . Nuclear receptor activation by EPO is of particular interest as enzymes and transporters involved in drug metabolism and disposition are transcriptionally regulated by xenosensing nuclear receptors. Specifically, CYP3A4 expression is regulated by pregnane X receptor (PXR), and both CYP3A and CYP2C enzymes are regulated by hepatocyte nuclear factor 4α (HNF-4α; Ibeanu and Goldstein, 1995; Tirona et al., 2003) . Despite these findings and the increasing number of CKD patients receiving EPO to treat anaemia, the effect of continuous EPO administration on the enzymes involved in drug metabolism in the presence, or absence, of CKD has not been directly investigated.
The objective of this study was to examine the effect of EPO on P450 expression and function in the presence, and absence, of CKD. We utilized an adenine-fed rat model of CKD combined with treatment of recombinant human EPO to evaluate its effects on hepatic expression and activity of CYP2C and CYP3A drug-metabolizing enzymes. We hypothesized that the treatment with EPO would partly restore CKDmediated down-regulation of P450 expression and activity.
Methods

Experimental model
All animal care and experimental protocols and procedures were approved by the Western University Animal Care Com- (Pawson et al., 2014) and are permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 ( a,b Alexander et al., 2013a,b) .
Tables of Links
mittee and conducted in accordance with the Canadian Council on Animal Care. Studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals McGrath et al., 2010) . A total of 32 animals were used in the experiments described here. Male Wistar rats, 6 weeks of age (weighing 150 g), were obtained from Charles River Laboratories, Inc. (Wilmington, MA, USA). Animals were acclimated for 4 days on a 12 h light cycle with standard rat chow and water ad libitum.
Adenine-induced CKD
After acclimation, rats were assigned to a normal chow diet (n = 16) or a chow diet supplemented with 0.7% adenine (n = 16) for 6 weeks. Rats were pair-fed, food was weighed daily and control rats were fed the same mass of food per day as their adenine-fed counterparts. After 4 weeks on the adenine or control diets, rats received either 150 U·kg −1 epoetin alfa, or saline, in a volume of 0.25 mL per 100 g body weight, by i.p. injection every other day for 2 weeks prior to euthanasia. The dose of EPO was selected to closely match the dose used in maintenance haemodialysis patients. The resulting treatments created four groups of equal number (n = 8) -chow-fed saline-injected rats (control), chow-fed EPO-injected rats (EPO), adenine-fed saline-injected rats (CKD) and adeninefed EPO-injected rats (CKD EPO). After the 6 week protocol, rats were sacrificed under isoflurane anaesthesia by decapitation. Blood was collected and haematocrit, plasma markers of CKD (creatinine and urea) and liver enzymes [aspartate transaminase (AST) and alanine transaminase (ALT) ] were determined by the London Laboratory Services group by standard methods (London, ON, Canada).
Histology
Fresh liver and kidney samples were fixed in 10% formalin obtained from Anachemia (Rouses Point, NY, USA). Tissue processing, sectioning and staining were completed by the Department of Pathology (Western University, Canada). Samples were dehydrated using ethanol, cleared with xylene and embedded in paraffin wax. Sections (5 μm) of the liver and kidney were cut, using a microtome, and mounted on slides before being rehydrated and stained with haematoxylin and eosin (H&E). Slides were visualized using an Olympus SZX16 microscope and Qcapture Pro software version 6.0 by QImaging (Redwood City, CA, USA).
Real-time PCR analysis
Hepatic total RNA was extracted using TRIzol Reagent from Life Technologies, Inc. (Burlington, ON, Canada) according to manufacturer's protocol. RNA concentration and quality were determined using a NanoDrop spectrophotometer from Thermo Scientific (West Palm Beach, FL, USA). cDNA was synthesized from 1 μg total RNA using qScript cDNA Supermix from Quanta Biosciences (Gaithersburg, MD, USA). Relative mRNA was quantified by real-time PCR with PerfeCta SYBR Green Fastmix from Quanta Biosciences (Gaithersburg, MD, USA). Specific primers were designed for CYP1A2, CYP2C11, CYP3A2, PXR, retinoid X receptor α (RXRα), constitutive androstane receptor (CAR), aryl hydrocarbon receptor (AhR) and HNF-4α using NCBI Primer-Blast. Gene expression was normalized to β-actin using the ΔΔCT method (Livak and Schmittgen, 2001) . Relative mRNA levels were analysed compared with the control treatment group that received normal chow and saline injections.
Hepatic microsome isolation
Liver microsomes were isolated by differential centrifugation as described previously (Velenosi et al., 2012) . Liver tissue was rinsed in 0.9% NaCl solution and homogenized in 1.15% KCl containing 1 mM EDTA. Tissue homogenate was centrifuged at 9000 g for 20 min at 4°C. The resulting supernatant was centrifuged at 105 000 g for 60 min at 4°C. The microsome pellet was resuspended in 250 μL of 100 mM potassium phosphate buffer containing 20% glycerol at pH 7.4. Total protein concentration was quantified using Pierce BCA protein assay from Fisher Scientific (Waltham, MA, USA) and microsomes were aliquoted and stored at −80°C until use.
Determination of total P450 content
Microsomal protein was used to determine total P450 content using spectral analysis after reduction of P450 using carbon monoxide and sodium dithionite (Omura and Sato, 1964) .
Western blot analysis
Microsomes were used for the determination of CYP1A, CYP2D, CYP2C11 and CYP3A2 protein expression using Western blot analysis. Twenty micrograms of microsomal protein were loaded per well in a 10% polyacrylamide gel containing 0.1% SDS and electrophoresed for 60 min at 120 V. Proteins were transferred to a nitrocellulose membrane for 60 min at 150 V and immunoblots were incubated at room temperature with primary antibodies for 90 min prior to being washed with PBS with 0.1% tween and incubated with secondary antibodies linked to HRP for 60 min. Primary antibodies used were polyclonal rabbit anti-rat CYP1A, dilution 1:5000, Detroit R&D, Inc. (Detroit, MI, USA), monoclonal mouse anti-rat CYP2C11, dilution 1:5000, Detroit R&D, Inc., polyclonal rabbit anti-rat CYP2D, dilution 1:5000, Detroit R&D, Inc., monoclonal rabbit anti-rat CYP3A2, dilution 1:10000, Millipore (Billerica, MA, USA), and monoclonal mouse anti-β-actin-peroxidase, dilution 1:50000, Sigma-Aldrich (St. Louis, MO, USA). HRP-linked secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Luminata Forte Western HRP substrate was obtained from Millipore (Billerica, MA). Chemiluminescence from immune blots was imaged on a Bio-Rad VersaDoc Imaging System (Berkeley, CA, USA) and band intensity was quantified by densitometry using Bio-Rad Quantity One 1D analysis software.
Microsomal metabolism and analysis by ultra-performance liquid chromatography with photodiode array detection (UPLC-PDA) and LC/MS
Metabolic activity of CYP3A and CYP2C in hepatic microsomes was determined using probe substrates as previously described (Velenosi et al., 2012) . Full-enzyme kinetics was completed individually for each of the eight rats in the four treatment groups. Testosterone and midazolam were selected as substrates for CYP3A, and testosterone was used as a substrate for CYP2C activity. Testosterone metabolites 16αOHtestosterone and 6βOH-testosterone are formed by the activity of CYP2C and CYP3A respectively. Buffered reactions, using 50 mM potassium phosphate with 2 mM MgCl2 (pH 7.4), were conducted with 1 mg·mL −1 final hepatic microsomal protein concentration in a final volume of 250 μL. Metabolism was determined previously to be linear at 10 min for the formation of testosterone metabolites and 30 min for the formation of midazolam metabolites. All reactions were pre-incubated with probe substrates for 10 min at 37°C and initiated by the addition of 1 mM NADPH (final concentration). Substrate concentrations used were 50, 100, 400 and 1000 μM for testosterone and 5, 10, 30, 100 and 300 μM for midazolam. Reactions were terminated by adding 50 μL of ice-cold acetonitrile followed by 15 min incubation on ice and centrifugation at 20 000× g for 5 min to pellet precipitated protein. Metabolites of testosterone, 6βOH-testosterone (CYP3A) and 16αOH-testosterone (CYP2C), were extracted by solid-phase extraction, using carbamazepine as an internal standard, followed by UPLC-PDA as described previously (Velenosi et al., 2012) . Briefly, analytes were separated on a Kinetex 2.1 × 50 mm, 1.7 μm, C18 UPLC column, maintained at 40°C, using KH2PO4 (pH 3.0) and acetonitrile mobile phase. The isocratic conditions were 93:7 (KH2PO4 : acetonitrile) for 2 min followed by a 20:80 wash for 1 min prior to a 1 min re-equilibration at initial conditions. Detection of testosterone metabolites and carbamazepine was achieved measuring absorbance at 240 and 287 nm respectively. Concentrations were determined from standard curves generated for quantification of 6βOH-testosterone (0.1-25 μM) and 16αOHtestosterone (0.2-100.0 μM).
Quantification of midazolam metabolism was achieved using a Waters UPLC with a Waters Xevo G2-S Qtof mass spectrometer; 1-hydroxymidazolam and internal standard, flurazepam, were extracted using solid-phase extraction cartridges. Analytes were separated on a Waters Acquity BEH 2.1 × 50mm, 1.7 μm, C18 UPLC column, maintained at 40°C, using water with 0.01% formic acid (pump A) and acetonitrile (pump B) mobile phase. Linear gradient conditions were 20% B to 35% B over 2.5 min. The column was then washed with 80% B for 1 min prior to re-equilibration to initial conditions for an additional minute. The mass spectrometer was operated in positive electrospray ionization mode. An accurate m/z of 342.0889 [M-H + ] and 388.1592 [M-H + ] was used to detect 1-hydroxymidazolam and flurazepam respectively. Leucine-enkephalin (556.2771, [M-H + ] ) was used as lockspray to ensure mass accuracy (<2 ppm) for all samples. Concentrations were determined from a standard curve generated for quantification of 1-hydroxymidazolam (0.1-100.0 μM).
Chromatin immunoprecipitation (ChIP)
ChIP was performed on rat liver tissue using previously published methods (Sohi et al., 2011) . In brief, tissue was homogenized and DNA cross-linked by 1% formaldehyde before being sheared by sonication. Sonicated chromatin was diluted, aliquoted and stored at −80°C. Samples were precleared with protein A/G agarose and incubated with 5 μg of antibody per aliquot, unless stated, of RNA Pol II, 1 μg per aliquot, Millipore; PXR (Santa Cruz Biotechnology, Inc.); HNF-4α (Santa Cruz Biotechnology, Inc.); or STAT5 (Santa Cruz Biotechnology, Inc.), overnight at 4°C. Separate aliquots of sample chromatin were incubated with the same amount, and same host species of normal IgG, Millipore, to determine non-specific binding. Protein A/G agarose beads (Santa Cruz Biotechnology, Inc.), were used to collect antibody, antigen and associated chromatin. Beads were washed and then eluted with SDS buffer. Antibody collected chromatin and sample inputs were heated to 65°C to reverse cross links. Proteinase K, purchased from Bio Basic (Markham, ON, Canada), was added for 1 h at 45°C and then DNA was extracted and precipitated prior to being reconstituted in Tris-EDTA buffer. Primers were designed, using NCBI primerblast, to amplify 100-200 bp regions of genomic DNA around known or putative binding sites of proteins of interest in the promoter region of CYP2C11 or CYP3A2. Real-time PCR was used to quantify RNA Pol II, PXR, HNF-4α and STAT5 promoter region binding.
Data analysis
Results are expressed as mean ± SEM. All statistical analysis was performed using GraphPad Prism (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA). A Michaelis-Menten model was used to fit the formation of testosterone and midazolam metabolites. Statistical differences between control and treated rats were assessed by one-way ANOVA followed by Tukey's post hoc test. P < 0.05 was considered significant.
Replicates were used in experimental assays to confirm the accuracy of single values. These single value averages were used as individual averages to comprise each n value for each of the eight values in each treatment group. Western blots and metabolism assays were performed in duplicate to determine an accurate value for each n value. Quantitative PCR results, used for mRNA expression analysis and ChIP, were performed in triplicate for each n value.
Materials
Adenine was obtained from Amresco (Solon, OH, USA). Testosterone, 6βOH-testosterone and 16αOH-testosterone were purchased from Steraloids, Inc. (Newport, RI, USA). Carbamazepine and flurazepam were purchased from Cerilliant (Round Rock, TX, USA). Epoetin alfa (EPREX ® ) was obtained from Janssen-Ortho (Markham, ON, Canada). Midazolam and 1-hydroxymidazolam were purchased from Toronto Research Chemicals, Inc. (Toronto, ON, Canada).
Results
Plasma biochemistry and body weight
Haematocrit was significantly increased in the EPO and CKD EPO groups (P < 0.001), and significantly decreased in the CKD group (P < 0.01) relative to control. Plasma creatinine levels were 931 and 845% of control in CKD and CKD EPO respectively (P < 0.001; Table 1 ). CKD and CKD EPO groups had plasma urea concentrations 1079 and 713% of control respectively (P < 0.001). Plasma liver enzymes AST and ALT were measured to demonstrate adenine diets, and EPO injections did not cause hepatocellular injury (Table 1) . Plasma liver enzyme levels in our study were within reference limits and comparable with previously published reports based on gender and body weight (Zhang et al., 2004) . Additionally, examination using H&E staining showed normal liver histology in all treatment groups (Figure 1 ). Kidney damage shown by histology demonstrates damaged, enlarged renal tubules and increased interstitial cell nuclei consistent with previous characterization of the adenine-fed model of kidney disease (Figure 1 ; Diwan et al., 2013) . No histological differences were observed in the liver of EPO, CKD or CKD EPO groups relative to control.
Spectral analysis of total P450 content in liver microsomes showed no decrease between control and EPO-treated groups. Consistent with the 5/6 nephrectomy rat model of CKD used previously (Leblond et al., 2001) , a 52% decrease in hepatic total P450 content was demonstrated in CKD and CKD EPO rats relative to control (P < 0.001; Table 1 ). There were no significant differences in body weight between groups.
Nuclear receptor mRNA expression
CKD EPO rats showed a 49% decrease in CAR hepatic mRNA expression compared with control (P < 0.05; Figure 2 ). CKD and CKD EPO rat groups had a, 48 and 41% decrease, in PXR hepatic mRNA expression respectively (P < 0.01; Figure 2 ). There were no significant differences in the hepatic mRNA expression of AhR (P = 0.24), RXRα (P = 0.10) or HNF-4α (P = 0.26) between treatment groups and control.
CYP1A, CYP2C11, CYP2D1 and CYP3A2 mRNA and protein expression CYP2C11 mRNA expression was decreased by 97 and 98% for CKD and CKD EPO rats, respectively, relative to control (P < 0.001; Figure 3B ). Similarly, hepatic CYP3A2 mRNA expression was significantly decreased, relative to control, by 98 and 99% in CKD and CKD EPO rats respectively. Hepatic CYP3A2 mRNA expression was also decreased by 55% in EPO-treated rats compared with control (P < 0.05; Figure 3D ). CYP2C11 mRNA expression was not different between control and EPO groups (P = 0.58). No differences were seen in hepatic CYP1A (P = 0.94; Figure 3A ) or CYP2D1 (P = 0.46) mRNA expression relative to control.
Similar to mRNA expression, hepatic protein expression of CYP2C11 was significantly decreased by 93 and 96% in the CKD and CKD EPO groups relative to control (P < 0.001; Figure 4B ). Hepatic CYP3A2 protein expression was significantly decreased by 79, 98 and 98% in the EPO, CKD and CKD EPO groups, respectively, relative to control (P < 0.001; Figure 4D ). CYP2C11 protein expression was not different between EPO and control groups (P = 0.56). No statistical differences were seen for CYP1A (P = 0.70; Figure 4A ) or CYP2D (P = 0.65; Figure 4C ) protein expression relative to control.
Hepatic CYP2C11 and CYP3A-mediated drug metabolism
We evaluated the function of CYP2C11, using testosterone and CYP3A, using testosterone and midazolam, in rat liver microsomes. Testosterone is specifically metabolized to 16αOH-testosterone by CYP2C11. Formation of 16αOHtestosterone by CYP2C11 in CKD and CKD EPO rat liver microsome samples was below the limit of detection for most substrate concentrations; therefore, Michaelis-Menten values could not be calculated and statistical analysis could not be performed for the CKD and CKD EPO groups. There was no difference in the Vmax for the formation of 16αOH-testosterone between EPO and control rat groups (P = 0.61). CYP2C11 Vmax was substantially higher in control and EPO groups, 1880.8 ± 241.6 and 1669.2 ± 317.9 pmol·min −1 ·mg·protein −1 , respectively, than the unquantifiable metabolite formation in CKD and CKD EPO groups ( Figure 5A ). The formation of 6βOH-testosterone and 1-hydroxymidazolam are largely catalysed by CYP3A enzymes. EPO Vmax for CYP3A-mediated formation of 6βOHtestosterone was significantly decreased by 32% relative to control (P < 0.05; Table 2 ). Further significant decreases in Vmax of 51 and 61% were seen in CKD and CKD EPO rats, respectively, compared with controls (P < 0.01; Figure 5B ). Maximal enzyme velocity for the formation of 1-hydroxymidazolam was significantly decreased by 71 and 76% in CKD and CKD EPO groups, relative to control respectively (P < 0.01; Figure 5C ). EPO Vmax for the formation of 1-hydroxymidazolam was decreased by 24%, but did not reach statistical significance (P = 0.24). Michaelis-Menten values for the formation of 16αOH-testosterone, 6βOHtestosterone and 1-hydroxymidazolam are summarized in Table 2 .
Chromatin immunoprecipitation of RNA Pol II, PXR, HNF-4α
To explore the effects of EPO and CKD on transcriptional regulation of CYP2C11 and CYP3A2, ChIP and quantitative real-time PCR was utilized to quantify binding of RNA Pol II and nuclear receptors, HNF-4α and PXR, to the promoter region of genes. RNA Pol II recruitment to the promoter region of CYP2C11 was decreased by 72 and 78%, relative to control, in CKD and CKD EPO groups respectively (P < 0.05; Figure 6A ). Similarly, RNA Pol II binding to the promoter of CYP3A2 was decreased by 88 and 90% in CKD and CKD EPO groups, respectively, compared with control (P < 0.001; Figure 7A ). Additionally, RNA Pol II binding to the CYP3A2 promoter was decreased by 52% in the EPO group relative to control (P < 0.01; Figure 7A ).
HNF-4α binding to the promoter region of both CYP2C11 and CYP3A2 was also assessed using ChIP. There was a 54 and 56% decrease in HNF-4α binding in the promoter region of CYP2C11 for CKD and CKD EPO groups, respectively, but this failed to reach significance ( Figure 6B) . In contrast, significant decreases in HNF-4α binding were seen in the promoter region of CYP3A2 with decreases in HNF-4α binding by 62, 71 and 90%, relative to control, in the EPO, CKD and CKD EPO treatment groups respectively (P < 0.05; Figure 7B ). Additionally, PXR binding to the CYP3A2 promoter showed 71, 88 and 90% decreased binding, relative to control, in EPO, CKD and CKD EPO groups respectively (P < 0.001; Figure 7C ).
Discussion and conclusions
Several earlier reports have described the decreased hepatic expression and function of CYP2C11 and CYP3A2 in rats with CKD using the 5/6 nephrectomy or ligation models of disease (Leblond et al., 2000; Guevin et al., 2002; Velenosi et al., 2012) . To our knowledge, this is the first study to use the adenine-fed model of CKD to study the effects of renal failure on drug metabolism. The 5/6 nephrectomy is the best characterized rodent model of CKD. Despite its widespread utility, the 5/6 nephrectomy models the consequence of CKD (i.e. nephron loss), but does not completely mimic the progression of CKD. The adenine-fed CKD model was used in this study for several reasons: (i) it is a less invasive model with lower rates of mortality; (ii) there is lower variability in creatinine and urea; and (iii) it produces pathological changes that are consistent with progressive CKD (Terai et al., 2008; Hewitson et al., 2009; Diwan et al., 2013) . To ensure that the adenine diet model did not also mediate liver toxicity, we confirmed that adenine-fed rats had normal liver histology. In addition, plasma biochemistry results support that the adenine-fed model of CKD and the dosing of EPO do not alter the morphology or affect the integrity of liver tissue.
Our first objective was to confirm that the changes in drug-metabolizing enzyme expression and function in the adenine-fed model of CKD were consistent with the 5/6
Figure 2
mRNA expression of hepatic nuclear receptors CAR, PXR, AhR, RXRα and HNF-4α. Expression is normalized to housekeeping gene β-actin and shown as relative to percentage of mean control expression for treatment groups EPO CKD and CKD EPO Results shown are mean ± SEM, n = 8. *P < 0.05, **P < 0.01, ***P < 0.001 compared with control; † P < 0.05 compared with EPO. nephrectomy model. Our data clearly demonstrate that the adenine-fed model of CKD causes pronounced decreases of hepatic CYP2C11 and CYP3A2 expression and function, consistent with previously published work using the 5/6 nephrectomy model of CKD (Leblond et al., 2001; Guevin et al., 2002; Velenosi et al., 2012) . Our next objective was to evaluate our hypothesis that EPO would partially restore expression of P450s down-regulated by CKD. We hypothesized EPO would restore P450 expression in CKD for two reasons. First, recent findings demonstrate that EPO is able to activate nuclear receptors known to be involved in the regulation of drug transport proteins involved in drug disposition (Naik et al., 2006; Lu et al., 2010; Meyer Zu Schwabedissen et al., 2010) . Second, induction of CYP3A6, the rabbit orthologue of human CYP3A4, was observed in a hypoxia study using isolated rabbit hepatocytes. The authors showed the involvement of plasma mediators (Fradette et al., 2002) and convincingly showed, using anti-EPO antibodies, that part of the CYP3A6 induction observed was due to the actions of EPO (Fradette et al., 2002) . Despite these previous findings and contrary to our hypothesis, we observed no restoration in CKD-mediated down-regulation of P450 enzymes. In fact, our results demonstrate that 2 weeks of IP EPO injections significantly decreases CYP3A2 mRNA expression, leading to a corresponding decrease in protein expression and metabolism of the CYP3A probe substrate testosterone. Although significant decreases were seen in mRNA and protein expression of CYP3A2, the metabolism of probe substrates did not demonstrate the same degree of difference between control and EPO-treated rats. This result is likely to be due to the actions of other P450 enzymes able to metabolize testosterone and midazolam to the metabolites, 6βOH-testosterone and 1OHmidazolam respectively (Chovan et al., 2007) . Previous work by Chovan et al. (2007) has reported that, for the hydroxylation of midazolam in rat liver microsomes, only 32% of metabolite formation is achieved by CYP3A2. Other P450
Figure 3
mRNA expression of hepatic CYP1A2 (A), CYP2C11 (B), CYP2D1 (C) and CYP3A2 (D) in control, EPO-, CKD-and CKD EPO-treated rats. Expression is normalized to β-actin and shown as a percentage of control means. Results are mean ± SEM, n = 8. *P < 0.05, **P < 0.01, ***P < 0.001, compared with control; † P < 0.05, † † P < 0.01, † † † P < 0.001 compared with EPO.
isozymes, such as CYP2C11 and CYP2C13 are also involved. In addition, the formation of 6βOH-testosterone is also accomplished by the activity of CYP2A2, CYP1A1 and others (Chovan et al., 2007) . Finally, both testosterone and midazolam are metabolized by CYP3A1 and its hepatic expression was not evaluated in the current study. Further, we demonstrate that treatment with EPO decreases PXR and HNF-4α binding to the CYP3A2 promoter and that this decrease in binding is concurrent with a decrease in RNA polymerase II binding. Although EPO has been shown to activate other nuclear receptors, such as LXR, our data demonstrate that it mediates decreased activity of hepatic PXR and HNF-4α. Despite the widespread use of rodent models for the study of CKD and hypoxia-induced changes in P450 expression, some differences in regulation, relative to the human, have been described. For example, although human and rodent PXR share a high sequence homology and similar target genes, interspecies differences in ligand-dependent activation exist Wrighton et al., 1985) . Accordingly, the differences we observed in nuclear receptor binding in our rat study need to be confirmed in a humanized system (e.g. humanized mouse models).
EPO treatment is targeted at increasing the proliferation and differentiation of erythrocytes in order to treat anaemia. Erythropoiesis requires iron, for haeme synthesis, as the prosthetic haeme group is required for the formation of haemoglobin. As P450 drug-metabolizing enzymes are also haemoproteins, one potential explanation of our data is that EPO administration simply depletes or limits the iron or haeme pool. The consequence of a depleted haeme pool would be a decrease in total P450 content with an increase in cytochrome P420. We found no significant difference in hepatic total P450 content between control and EPO-treated groups indicating that EPO itself does not simply decrease the iron or haem pool available for P450 synthesis. A significant decrease in total hepatic P450 content was observed in CKD and CKD EPO groups; however, this finding was expected and is consistent with previous studies using the 5/6 nephrectomy model of CKD (Leblond et al., 2000) . Iron deficiency is known to significantly decrease plasma iron, total liver iron and liver ferritin (Dhur et al., 1989) . However, iron deficiency has been shown in many studies to not affect total hepatic microsomal protein or P450 content (Catz et al., 1970; Dhur et al., 1989) . Further, limiting haeme has only been shown to decrease P450 induction by phenobarbital, not basal expression, in knockout mice unable to synthesize haem (Jover et al., 2000) . Additionally, the rats in our study were not subject to iron restriction; thus, it is unlikely that changes in P450 protein content were influenced by utilization of iron for erythropoiesis. Although we did not measure iron in our study, a previous study in rats with CKD receiving EPO did not display any changes in serum iron concentration (Srai et al., 2010) .
Previous reports demonstrate an up-regulation of hepatic CYP3A6 in rabbits exposed to hypoxia (Kurdi et al., 1999; Fradette et al., 2002) . One of the primary consequences of hypoxia is the stabilization of hypoxia-inducible factor (HIF) α subunits. HIF-1α and HIF-2α heterodimerize with HIF-1β and bind to HIF-responsive elements in target genes such as EPO to up-regulate their transcription. Indeed, increased synthesis of EPO is consistently observed in hypoxic conditions.
Figure 4
Protein expression of hepatic CYP1A (A), CYP2C11 (B), CYP2D (C) and CYP3A2 (D) in control, EPO-, CKD-and CKD EPO-treated rats. Protein bands are standardized to β-actin and expressed as relative densitometry units with the average of control bands arbitrarily defined as 100%. Results shown are mean ± SEM, n = 8. ***P < 0.001 compared with control; † † † P < 0.001 compared with EPO. Fradette et al. (2002) elegantly demonstrate that anti-EPO antibodies partially abrogate the induction of CYP3A6 under hypoxic conditions. Although our data appear to contradict this finding, it must be noted that there are marked species differences in the transcriptional regulation of P450s, and our study did not directly investigate the effect of hypoxia. Consistent with our observations, the expression and function of drug-metabolizing enzymes, including CYP3A4, are decreased after exposure to hypoxia in differentiated human HepaRG cells (Legendre et al., 2009) . In that study, hypoxiamediated down-regulation of CYP3A4 was shown to involve HIF-1α. Although implicated in the down-regulation of CYP3A, HIF-1α involvement in that study was thought to be acting by an indirect, and unknown, mechanism (Legendre et al., 2009) . Despite being an in vitro experiment using a hepatic cell line, it is possible that this unknown mechanism involves EPO signalling. Hypoxia, caused by low oxygen tension or anaemia secondary to bilateral nephrectomy or haemorrhage, has been previously shown to increase hepatic EPO production (Fried, 1972; Bondurant and Koury, 1986) .
Based on the previous work by Legendre et al. (2009) on the effect of hypoxia on CYP3A4 in HepaRG cells, our data suggest that EPO could be the next step in the elusive mechanism that links hypoxia and HIF activation to decreased CYP3A expression. Although constitutively expressed, HIF-1α subunits are extremely sensitive to oxygen and, in the presence of oxygen, are hydroxylated, recognized for ubiquitination and subsequently proteosomally degraded (Jaakkola et al., 2001) . Conversely, under hypoxic conditions HIF-1α and HIF-2α act as transcription factors to activate many genes including activating the transcription of EPO as shown in states of low oxygen tension (Lacombe et al., 1988; Wang and Semenza, 1993) . The relationship between HIFs and EPO, and corresponding evidence of decreases in CYP3A4 and CYP3A2, respectively, suggests that EPO is largely responsible for hypoxia-mediated changes in the expression of CYP3A. Our data support that exposure to EPO causes decreased binding of PXR, HNF-4α and RNA polymerase II to the promoter region of CYP3A2. It remains to be determined whether the effect of EPO on CYP3A expression is a direct result of EPO signalling or are a consequence of changes in the expression of other genes mediated by EPO. Interestingly, EPO did not alter the expression of, or the transcription factor binding to the promoter region of CYP2C11. Although the regulation of these enzymes has notable differences, they are both regulated to some degree by HNF-4α. This suggests that the mechanism of EPO-mediated down-regulation of CYP3A2 may target other currently unknown factors specific to regulation of CYP3A2 that are not involved in the regulation of CYP2C11.
The EPO receptor is expressed on many nonhaematopoietic tissues including liver. Upon ligand binding, EPO can activate three major intracellular signalling pathways: (i) the JAK2; (ii) the ERK; and (iii) the PI3K/Akt pathways. Activation of the JAK2 pathway activates STAT5 by phosphorylation (Gouilleux et al., 1995; Parganas et al., 1998) . Phosphorylated STAT5 is able to enter the nucleus and act as a transcription factor in the promoter region of genes both as an activator and a suppressor of transcription (John et al., 1999) . We attempted to characterize STAT5 binding to putative sites in the CYP3A promoter, but have been unable to confirm binding to these sites (data not shown). Activation of the ERK1/2 pathway has been shown to interact with phosphorylated CAR, preventing its dephosphorylation and retaining it in the cytoplasm (Osabe and Negishi, 2011) . PXR translocation to the nucleus is also decreased by phosphorylation (Lichti-Kaiser et al., 2009 ). Therefore, it is possible that EPO-induced ERK activation plays a role in retaining
Figure 5
Michaelis-Menten plots of the formation of 16αOH-testosterone (A), 6βOH-testosterone (B) and 1OH-midazolam (C) after incubation of rat liver microsomes with 1 mM NADPH and substrate concentrations of 50, 100, 400 and 1000 μM for testosterone and 5, 10, 30, 100 and 300 μM for midazolam. Formation of 16αOH-testosterone in CKD and CKD EPO liver microsomes was at or below the limit of detection for most concentrations. Results are presented as mean ± SEM, n = 8.
nuclear receptors in the cytoplasm and therefore decreasing CYP3A2 transcription. The last cell signalling pathway activated by EPO is the PI3K/Akt pathway. Previous studies have shown that downstream kinases in this pathway phosphorylate and negatively regulate the transcriptional activity of PXR (Lichti-Kaiser et al., 2009; Pondugula et al., 2009) . Finally, a recent study has shown that EPO activates the LXR in macrophages (Lu et al., 2010) . The LXR has been shown to transcriptionally repress the activity of both PXR and CAR, which provides another potential explanation of the molecular mechanism linking EPO to decreased CYP3A2 expression in our study (Handschin et al., 2002; Pondugula et al., 2009) . It is clear that EPO mediates its non-haematopoietic effects via many distinct molecular pathways and that further work is needed to isolate the specific mechanism associated with EPO-induced decreases in nuclear receptor binding and CYP3A expression.
In conclusion, this study demonstrates that EPO decreases the expression and function of hepatic CYP3A2 by decreasing the binding of the nuclear receptors PXR and HNF-4α. To our knowledge, this is the first study that has evaluated the effect of EPO on drug metabolism. As the principal enzyme for the metabolism of many drugs, knowledge of the effects of EPO on CYP3A expression and function are important for patient safety and appropriate drug dosing. Greater understanding on how EPO affects hepatic P450 expression in vitro and Table 2 Michaelis-Menten kinetic values for formation of 16α-OH testosterone (CYP2C11), 6β-OH testosterone (CYP3A) and 1-OH midazolam (CYP3A) in control, EPO, CKD and CKD EPO rat liver microsomes 
Figure 6
ChIP in hepatic tissue to quantify the binding of RNA pol II (A) and HNF-4α binding (B) to the promoter region of CYP2C11 for control, EPO (red), CKD and CKD EPO rats. Results are standardized to input DNA and expressed as a percentage of mean control value. Samples immunoprecipitated with normal mouse IgG (A) or rabbit IgG (B) are shown as IgG (white). Results are mean ± SEM, n = 8. *P < 0.05 relative to control.
in vivo, will be needed before evaluating the pharmacokinetics of individual drugs to optimize drug dosing in patients receiving recombinant human EPO.
Figure 7
ChIP in hepatic tissue to quantify the binding of RNA pol II (A), HNF-4α binding (B) and PXR (C) to the promoter region of CYP3A2 for control, EPO, CKD and CKD EPO rats. Results are standardized to input DNA and expressed as a percentage of mean control value. Samples immunoprecipitated with normal mouse IgG (A) or rabbit IgG (B and C) are shown as IgG. Results are mean ± SEM, n = 8. *P < 0.05, **P < 0.01, ***P < 0.001, compared with control.
